Literature DB >> 27677661

Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection.

Ze-Xin Zhu1, Ji-Wei Huang1, Ming-Heng Liao1, Yong Zeng2.   

Abstract

Hepatocellular carcinoma is the most common malignancy in liver, is also a global problem and is the fourth most commonly diagnosed cancers among men and the fourth leading causes of cancer death among both men and women in China. Liver resection or hepatic resection and radiofrequency ablation is widely accepted as a first-line surgical approach for hepatocellular carcinoma in China. However, the indications of radiofrequency ablation or hepatic resection are different and not unified in China. In this article, we review the current status of hepatic resection and radiofrequency ablation therapies in hepatocellular carcinoma management in China.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  China; hepatic resection (HR); hepatocellular carcinoma (HCC); liver resection (LR); radiofrequency ablation (RFA)

Mesh:

Year:  2016        PMID: 27677661     DOI: 10.1093/jjco/hyw134

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  28 in total

1.  The clinical significance and biological function of large tumour suppressor 2 in hepatocellular carcinoma.

Authors:  Rong Liang; Yan Lin; Chun-Ling Yuan; Zhi-Hui Liu; Yong-Qiang Li; Xiao-Ling Luo; Jia-Zhou Ye; Hai-Hong Ye
Journal:  Cell Prolif       Date:  2017-03-01       Impact factor: 6.831

2.  Effects of recombinant human adenovirus type 5 combined with transarterial chemoembolization on postoperative metastasis and recurrence of hepatocellular carcinoma patients.

Authors:  Ke Wu; Nan You; Lu Zheng
Journal:  J Gastrointest Oncol       Date:  2021-12

Review 3.  The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma.

Authors:  BoZhi Liu; YongChao Zhang; Hui Chen; Wei Li; Emmanuel Tsochatzis
Journal:  Cochrane Database Syst Rev       Date:  2022-01-04

4.  Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma.

Authors:  Jingjing Guo; Saixia Wang; Yujing Han; Zhongyuan Jia; Runchao Wang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

5.  Multi-phase contrast-enhanced magnetic resonance image-based radiomics-combined machine learning reveals microscopic ultra-early hepatocellular carcinoma lesions.

Authors:  Kui Sun; Liting Shi; Jianfeng Qiu; Yuteng Pan; Ximing Wang; Haiyan Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-01       Impact factor: 10.057

6.  Transcatheter Arterial Chemoembolization Combined with Simultaneous Computed Tomography-guided Radiofrequency Ablation for Large Hepatocellular Carcinomas.

Authors:  Tai-Yang Zuo; Feng-Yong Liu; Mao-Qiang Wang; Xian-Xian Chen
Journal:  Chin Med J (Engl)       Date:  2017-11-20       Impact factor: 2.628

7.  Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma.

Authors:  Bao-Min Shi; Wen Lu; Kun Ji; Yu-Feng Wang; Shuai Xiao; Xiu-Yan Wang
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

8.  The Upregulation of Trophinin-Associated Protein (TROAP) Predicts a Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Hao Hu; Liang Xu; Yan Chen; Shao-Ju Luo; Ying-Zi Wu; Shi-Hua Xu; Meng-Ting Liu; Fen Lin; Yan Mei; Qin Yang; Yuan-Yuan Qiang; You-Wu Lin; Yuan-Jiang Deng; Tong Lin; Yong-Qiang Sha; Bi-Jun Huang; Shi-Jun Zhang
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

Review 9.  The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma.

Authors:  Zhentian Xu; Haiyang Xie; Lin Zhou; Xinhua Chen; Shusen Zheng
Journal:  Anal Cell Pathol (Amst)       Date:  2019-08-26       Impact factor: 2.916

10.  microRNA-944 inhibits the malignancy of hepatocellular carcinoma by directly targeting IGF-1R and deactivating the PI3K/Akt signaling pathway.

Authors:  Lili Lv; Xiaodong Wang; Tonghui Ma
Journal:  Cancer Manag Res       Date:  2019-03-29       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.